Docteur Elisabetta LANCIANO
✨ Profil synthétique
IA · 29/04/2026Le Docteur Elisabetta LANCIANO est rhumatologue à l'hôpital de Saint-Michel. Ses publications sur PubMed montrent un intérêt pour les biothérapies non-anti-TNF et la maladie de Sjögren. Elle contribue ainsi aux avancées dans le domaine de la rhumatologie.
Expertises présumées
- Biothérapies non-anti-TNF
- Sjögren
- Rhumeumatisme auto-immun
- Thérapies biologiques
- Maladies auto-immunes
- Pathologies articulaires
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- Rhumatologie (SM)
🎓 Diplômes
- Diplôme éq d'un pays de l'EEE profession Médecin
📝 Autres formations
- DEES Rhumatologie
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Lieu de consultation
CENTRE HOSPITALIER D'ANGOULEME
Rond point DE GIRAC, 16959 Saint-Michel
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection
Arthritis care & research · 2016
Lire l'abstract Crossref ↓
ObjectiveRheumatoid arthritis (RA) with concomitant hepatitis B virus (HBV) infection represents a therapeutic challenge due to the risk of HBV reactivation under immunosuppressive treatment. To date there are few data coming from anecdotal case reports that concern HBV reactivation following treatment with abatacept. This observational retrospective study was aimed to assess the safety profile of abatacept in this particular clinical setting.MethodsEleven Italian rheumatologic centers provided data from patients with RA and positive HBV serology treated with intravenous abatacept. HBV markers and clinical and laboratory data were checked at followup visits every 3 months.ResultsIn total, 72 patients were included in the study: 47 inactive carriers, 21 occult carriers, and 4 chronic active carriers for HBV. At baseline all of the patients had normal liver function tests and low or undetectable HBV DNA levels, except for those with chronic active hepatitis. Thirteen patients received prophylaxis with lamivudine, and 4 received treatment with adefovir or tenofovir. At the end of the 24‐month followup period, 49 patients were being treated. Data from 316 followup visits showed that abatacept was safe. No patients experienced reactivation of hepatitis B. Treatment withdrawals (23 patients) were due to lack of efficacy, subject decision/lost at followup, or adverse events not related to HBV infection.ConclusionOur study provides reassuring data about the safety profile of abatacept in RA with concomitant HBV infection without universal antiviral prophylaxis. Further prospective studies are needed to confirm these preliminary results.
- 2Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series
Rheumatology international · 2012
📚 6 citations
Publications scientifiques (2) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Biothérapies non-anti-TNF2
▼
Biothérapies non-anti-TNF2
▼- Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection
Arthritis care & research · 2016 · Journal Article
Padovan M, Filippini M, Tincani A, Lanciano E, et al.
📚 40 cit.🎯 RCR 1.67🩺 Clinique - Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series
Rheumatology international · 2012 · Case Reports
Covelli M, Lanciano E, Tartaglia P, Grattagliano V, et al.
📚 6 cit.
Sjögren1
▼
Sjögren1
▼- Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series
Rheumatology international · 2012 · Case Reports
Covelli M, Lanciano E, Tartaglia P, Grattagliano V, et al.
📚 6 cit.